We are live on ! Find out more
AGIO icon

Agios Pharmaceuticals
AGIO

152 hedge funds and large institutions have $1.68B invested in Agios Pharmaceuticals in 2023 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 63 increasing their positions, 50 reducing their positions, and 22 closing their positions.

New
Increased
Maintained
Reduced
Closed

26% more repeat investments, than reductions

Existing positions increased: 63 | Existing positions reduced: 50

24% more capital invested

Capital invested by funds: $1.36B → $1.68B (+$325M)

0.36% more ownership

Funds ownership: 106.45% → 106.81% (+0.36%)

7% less funds holding

Funds holding: 163 → 152 (-11)

45% less first-time investments, than exits

New positions opened: 12 | Existing positions closed: 22

56% less call options, than puts

Call options by funds: $5.2M | Put options by funds: $11.9M

Holders
152
Holders Change
-11
Holders Change %
-6.75%
% of All Funds
2.39%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
12
Increased
63
Reduced
50
Closed
22
Calls
$5.2M
Puts
$11.9M
Net Calls
-$6.72M
Net Calls Change
-$2.9M

Top Buyers

Rank Fund Capital Flow
1
JP Morgan Chase
JP Morgan Chase
New York
+$32.2M
2
FCM
Farallon Capital Management
California
+$14.8M
3
First Trust Advisors
First Trust Advisors
Illinois
+$8.04M
4
PAMS
Pictet Asset Management (Switzerland)
Switzerland
+$4.64M
5
Macquarie Group
Macquarie Group
Australia
+$4.47M

Top Sellers

Rank Fund Capital Flow
1
State Street
State Street
Massachusetts
-$12M
2
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
-$11.7M
3
N
Nuveen
North Carolina
-$5.11M
4
AC
Armistice Capital
New York
-$5.08M
5
IHAM
Integral Health Asset Management
New York
-$4.89M
Name Holding Trade Value Shares
Change 		Change in
Stake
Morgan Stanley
26
Morgan Stanley
New York
$11.1M +$2.01M +80,685 +26%
Axa
27
Axa
France
$10.1M +$48.6K +1,955 +0.6%
Ameriprise
28
Ameriprise
Minnesota
$9.21M +$485K +19,507 +6%
EHI
29
Eagle Health Investments
Connecticut
$7.58M – – –
Hudson Bay Capital Management
30
Hudson Bay Capital Management
Connecticut
$7.36M -$249K -10,000 -4%
Bank of America
31
Bank of America
North Carolina
$7.17M -$4.24M -170,426 -40%
Nordea Investment Management
32
Nordea Investment Management
Sweden
$6.97M -$1.47M -59,100 -19%
Balyasny Asset Management
33
Balyasny Asset Management
Illinois
$6.18M -$2.56M -102,907 -32%
Bank of New York Mellon
34
Bank of New York Mellon
New York
$5.95M +$80.4K +3,232 +2%
UBS AM
35
UBS AM
Illinois
$5.75M – – –
Norges Bank
36
Norges Bank
Norway
$5.75M -$1.93M -77,640 -28%
Citadel Advisors
37
Citadel Advisors
Florida
$4.96M -$2.69M -107,963 -38%
Millennium Management
38
Millennium Management
New York
$4.93M +$2.79M +112,316 +182%
Man Group
39
Man Group
United Kingdom
$4.83M +$4.25M +170,631 New
Rafferty Asset Management
40
Rafferty Asset Management
New York
$4.63M -$1.06M -42,538 -21%
Barclays
41
Barclays
United Kingdom
$4.5M +$1.57M +62,896 +66%
N
42
Nuveen
North Carolina
$4.42M -$5.11M -205,156 -57%
Jacobs Levy Equity Management
43
Jacobs Levy Equity Management
New Jersey
$4.1M -$11.7M -469,922 -76%
Wells Fargo
44
Wells Fargo
California
$4.03M -$198K -7,947 -5%
CS
45
Credit Suisse
Switzerland
$3.42M +$456K +18,334 +18%
ECM
46
ExodusPoint Capital Management
New York
$3.41M -$1.94M -78,003 -39%
Swiss National Bank
47
Swiss National Bank
Switzerland
$3.41M +$341K +13,700 +13%
Prudential Financial
48
Prudential Financial
New Jersey
$3.2M +$2.81M +112,852 New
Allianz Asset Management
49
Allianz Asset Management
Germany
$3.15M +$53.5K +2,150 +2%
RhumbLine Advisers
50
RhumbLine Advisers
Massachusetts
$2.86M +$236K +9,477 +10%
1
2
3 4 5

AGIO Hedge Fund Activity: Q2 2023 in Review

152 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Agios Pharmaceuticals (AGIO) for Q2 2023, worth a combined $1.68B — up 24% from $1.36B a quarter earlier.

Sellers outnumbered buyers: 22 funds closed out of AGIO and 12 opened new positions — a net loss of 10 holders — while 50 trimmed existing stakes and 63 added.

The largest buyer was JP Morgan Chase, adding an estimated $32.2M. The largest seller was State Street, cutting an estimated $12M.

  • 152 institutional investors held Agios Pharmaceuticals (AGIO) as of Q2 2023, down from 163 in Q1 2023.
  • Funds reported $1.68B of Agios Pharmaceuticals stock for Q2 2023, up 24% quarter-over-quarter.
  • 12 funds opened new Agios Pharmaceuticals positions in Q2 2023 and 22 closed out, a net change of -10 holders.
  • The largest Agios Pharmaceuticals buyer in Q2 2023 was JP Morgan Chase, an estimated $32.2M added.
  • The largest Agios Pharmaceuticals seller in Q2 2023 was State Street, an estimated $12M sold.

Based on aggregated 13F filings for Q2 2023.